These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30090324)

  • 21. Novel QSAR Models for Molecular Initiating Event Modeling in Two Intersecting Adverse Outcome Pathways Based Pulmonary Fibrosis Prediction for Biocidal Mixtures.
    Seo M; Chae CH; Lee Y; Kim HR; Kim J
    Toxics; 2021 Mar; 9(3):. PubMed ID: 33809804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of the use of in silico methods to predict the chemistry of molecular initiating events related to drug toxicity.
    Ellison CM; Enoch SJ; Cronin MT
    Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1481-95. PubMed ID: 22032332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanistic study of chlordecone-induced endocrine disruption: Based on an adverse outcome pathway network.
    Yang L; Zhou B; Zha J; Wang Z
    Chemosphere; 2016 Oct; 161():372-381. PubMed ID: 27448318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A fluorescence high throughput screening method for the detection of reactive electrophiles as potential skin sensitizers.
    Avonto C; Chittiboyina AG; Rua D; Khan IA
    Toxicol Appl Pharmacol; 2015 Dec; 289(2):177-84. PubMed ID: 26455772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse outcome pathway development from protein alkylation to liver fibrosis.
    Horvat T; Landesmann B; Lostia A; Vinken M; Munn S; Whelan M
    Arch Toxicol; 2017 Apr; 91(4):1523-1543. PubMed ID: 27542122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skin sensitizing effects of sulfur mustard and other alkylating agents in accordance to OECD guidelines.
    Steinritz D; Lang S; Popp T; Siegert M; Rothmiller S; Kranawetvogl A; Schmidt A; John H; Gudermann T; Thiermann H; Kehe K
    Toxicol Lett; 2019 Oct; 314():172-180. PubMed ID: 31404593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using 2D Structural Alerts to Define Chemical Categories for Molecular Initiating Events.
    Allen TEH; Goodman JM; Gutsell S; Russell PJ
    Toxicol Sci; 2018 Sep; 165(1):213-223. PubMed ID: 30020496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploration of the DARTable Genome- a Resource Enabling Data-Driven NAMs for Developmental and Reproductive Toxicity Prediction.
    Janowska-Sejda EI; Adeleye Y; Currie RA
    Front Toxicol; 2021; 3():806311. PubMed ID: 35295108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Development and application of adverse outcome pathway in toxicology research].
    Wang Y; Duan H
    Zhonghua Yu Fang Yi Xue Za Zhi; 2015 Dec; 49(12):1115-8. PubMed ID: 26887310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A conceptual framework for predicting the toxicity of reactive chemicals: modeling soft electrophilicity.
    Schultz TW; Carlson RE; Cronin MT; Hermens JL; Johnson R; O'Brien PJ; Roberts DW; Siraki A; Wallace KB; Veith GD
    SAR QSAR Environ Res; 2006 Aug; 17(4):413-28. PubMed ID: 16920662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The adverse outcome pathway for rodent liver tumor promotion by sustained activation of the aryl hydrocarbon receptor.
    Becker RA; Patlewicz G; Simon TW; Rowlands JC; Budinsky RA
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):172-90. PubMed ID: 26145830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is there a role for the adverse outcome pathway framework to support radiation protection?
    Chauhan V; Said Z; Daka J; Sadi B; Bijlani D; Marchetti F; Beaton D; Gaw A; Li C; Burtt J; Leblanc J; Desrosiers M; Stuart M; Brossard M; Vuong NQ; Wilkins R; Qutob S; McNamee J; Wang Y; Yauk C
    Int J Radiat Biol; 2019 Feb; 95(2):225-232. PubMed ID: 30373433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse Outcome Pathway-Driven Analysis of Liver Steatosis in Vitro: A Case Study with Cyproconazole.
    Luckert C; Braeuning A; de Sousa G; Durinck S; Katsanou ES; Konstantinidou P; Machera K; Milani ES; Peijnenburg AACM; Rahmani R; Rajkovic A; Rijkers D; Spyropoulou A; Stamou M; Stoopen G; Sturla S; Wollscheid B; Zucchini-Pascal N; Lampen A
    Chem Res Toxicol; 2018 Aug; 31(8):784-798. PubMed ID: 29995386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mining Public Toxicogenomic Data Reveals Insights and Challenges in Delineating Liver Steatosis Adverse Outcome Pathways.
    AbdulHameed MDM; Pannala VR; Wallqvist A
    Front Genet; 2019; 10():1007. PubMed ID: 31681434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of reactive drug metabolites in immune-mediated adverse drug reactions.
    Hess DA; Rieder MJ
    Ann Pharmacother; 1997 Nov; 31(11):1378-87. PubMed ID: 9391694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tributyltin: Advancing the Science on Assessing Endocrine Disruption with an Unconventional Endocrine-Disrupting Compound.
    Lagadic L; Katsiadaki I; Biever R; Guiney PD; Karouna-Renier N; Schwarz T; Meador JP
    Rev Environ Contam Toxicol; 2018; 245():65-127. PubMed ID: 29119384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of an Enhanced Mechanistically Driven Mode of Action Classification Scheme for Adverse Effects on Environmental Species.
    Sapounidou M; Ebbrell DJ; Bonnell MA; Campos B; Firman JW; Gutsell S; Hodges G; Roberts J; Cronin MTD
    Environ Sci Technol; 2021 Feb; 55(3):1897-1907. PubMed ID: 33478211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment.
    Ankley GT; Bennett RS; Erickson RJ; Hoff DJ; Hornung MW; Johnson RD; Mount DR; Nichols JW; Russom CL; Schmieder PK; Serrrano JA; Tietge JE; Villeneuve DL
    Environ Toxicol Chem; 2010 Mar; 29(3):730-41. PubMed ID: 20821501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicophores: investigations in drug safety.
    Williams DP
    Toxicology; 2006 Sep; 226(1):1-11. PubMed ID: 16860917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Adverse Outcome Pathway Linking Organohalogen Exposure to Mitochondrial Disease.
    McMinn B; Duval AL; Sayes CM
    J Toxicol; 2019; 2019():9246495. PubMed ID: 31057609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.